Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedOct 24, 2018CVS HealthCGMP Deviations: products manufactured under conditions that could impact its product quality.Product Quest Manufacturing LLC · D-0031-2019Class IITerminatedOct 24, 2018CVS HealthCGMP Deviations: products manufactured under conditions that could impact its product quality.Product Quest Manufacturing LLC · D-0030-2019Class IITerminatedOct 24, 2018CareOne, Saline Nasal Gel With Soothing AloeCGMP Deviations: products manufactured under conditions that could impact its product quality.Product Quest Manufacturing LLC · D-0029-2019Class IITerminatedOct 24, 2018RhinallCGMP Deviations: products manufactured under conditions that could impact its product quality.Product Quest Manufacturing LLC · D-0028-2019Class IITerminatedOct 24, 2018DERMATONEMicrobial Contamination of Non-Sterile Products: sample tested positive for Staphylococcus aureus.Product Quest Manufacturing LLC · D-0027-2019Class IIITerminatedOct 24, 2018Levonorgestrel and Ethinyl Estradiol TabletsLabeling: Not Elsewhere Classified-Incorrect NDC and product name identified on blister packs.Mylan Pharmaceuticals Inc. · D-0025-2019Class IITerminatedOct 24, 2018Thyroid, USPCGMP Deviations: Recall notice received from supplier that Thyroid Powder has inconsistent levels of the active ingredients levothyroxine and liothyronine.Humco Holding Group, Inc · D-0024-2019Class IITerminatedOct 24, 2018Thyroid, USPCGMP Deviations: Recall notice received from supplier that Thyroid Powder has inconsistent levels of the active ingredients levothyroxine and liothyronine.Humco Holding Group, Inc · D-0023-2019Class IITerminatedOct 24, 2018Thyroid, USPCGMP Deviations: Recall notice received from supplier that Thyroid Powder has inconsistent levels of the active ingredients levothyroxine and liothyronine.Humco Holding Group, Inc · D-0022-2019Class IITerminatedOct 17, 2018Prevacid 24HRCGMP deviationsGlaxosmithkline Nebraska · D-0088-2019Class IITerminatedOct 17, 2018Actoplus met XRDefective Delivery System: tablets may be missing, in whole or in part, the laser drilled holes on the metformin core of the Actoplus met XR tablets.Takeda Development Center Americas, Inc. · D-0026-2019Class IIITerminatedOct 17, 2018Altavera Levonorgestrel and Ethinyl Estradiol TabletsLabeling: Not Elsewhere Classified: mislabeling of the Altavera generic name on the packaging component that may cause confusion.Xiromed LLC · D-0016-2019Class IITerminatedOct 17, 2018Magnesium Sulfate in Water for InjectionCorrect Labeled Product Mispack: confirmed report involving a single unit of properly labeled Heparin in 0.45% Sodium Chloride for Injection (NDC 0409-7651-03, Lot...Pfizer Inc. · D-0015-2019Class IITerminatedOct 17, 2018THYROID POWDER USPCGMP Deviations: Recall notice received from supplier that Thyroid Powder has inconsistent levels of the active ingredients levothyroxine and liothyronine.Syntec Pharma Corp · D-0014-2019Class IITerminatedOct 17, 2018THYROID POWDER USPCGMP Deviations: Recall notice received from supplier that Thyroid Powder has inconsistent levels of the active ingredients levothyroxine and liothyronine.Syntec Pharma Corp · D-0013-2019Class IIITerminatedOct 17, 2018Amlodipine Besylate USP 10 mg TabletsSubpotent Drug: One lot of product does not meet the product specification for Assay test at 3 month long term stability condition.InvaGen Pharmaceuticals, Inc. · D-0012-2019Class IITerminatedOct 17, 2018Pantoprazole Sodium Delayed-Release TabletsDiscoloration: Presence of dark discoloration or brown spots on the edges of the tablets.Jubilant Cadista Pharmaceuticals, Inc. · D-0011-2019Class IITerminatedOct 17, 2018Glipizide XLCGMP Deviations; rejected product was used to manufacture final bulk lotPfizer Inc. · D-0010-2019Class IITerminatedOct 17, 2018Thyroid powderCGMP Deviations: Recall notice received from supplier that Thyroid Powder has inconsistent levels of the active ingredients levothyroxine and liothyronine.Alkano Chemicals, Inc · D-0008-2019Class IIITerminatedOct 10, 2018treatNOW ABILIFYLabeling Not Elsewhere Classified: Physician sample kits/cartons of treatNOW Abilify are mislabeled. Product name is misspelled, storage instructions are missing and...Otsuka Pharmaceutical Development & Commercialization, Inc. · D-0018-2019Class IIITerminatedOct 10, 2018treatNOW ABILIFYLabeling Not Elsewhere Classified: Physician sample kits/cartons of treatNOW Abilify are mislabeled. Product name is misspelled, storage instructions are missing and...Otsuka Pharmaceutical Development & Commercialization, Inc. · D-0017-2019Class ITerminatedOct 10, 2018robaxin-750Labeling: Incorrect Instructions: Dosage information on the immediate container label incorrectly states "Two to four tablets four times daily." rather than the correct...Endo Pharmaceuticals, Inc. · D-0009-2019Class IITerminatedOct 10, 2018Nystatin and Triamcinolone Acetonide CreamFailed stability specifications - An out of specification result was observed for the test parameter : composition of Nystatin during stability testing.Dr. Reddy's Laboratories, Inc. · D-0007-2019Class IITerminatedOct 10, 2018Thyroid Powder 25kg/drumCGMP Deviations: Thyroid Powder has inconsistent levels of the active ingredients levothyroxine and liothyronine.Sichuan Friendly Pharmaceutical Co.,Ltd. · D-0006-2019Class IITerminatedOct 10, 2018ElelysoLack of assurance of sterility -Reports of loose metal ferrule crimps on vials for injection. The entire cap either lifted or dislodged while attempting to flip off the...Pfizer Inc. · D-0005-2019Class IITerminatedOct 10, 2018NeoRelief for Muscle Cramping & Restlessness Homeopathic Topical GelCGMP Deviations: finished product produced with active ingredients recalled by the manufacturer, King Bio Inc., due to water contamination issues that could potentially...BioLyte Laboratories, LLC · D-0002-2019Class IITerminatedOct 10, 2018Clozapine Orally Disintegrating TabletsFailed Disintegration Specifications: Out-of-specification disintegration test result obtained during routine stability testing.Teva Pharmaceuticals USA · D-0001-2019Class IITerminatedOct 3, 2018SynjardyCross Contamination With Other Products:Boehringer Ingelheim Pharmaceuticals, Inc. · D-1217-2018Class IIITerminatedOct 3, 2018Levofloxacin Injection in 5% DextroseSuperpotent Drug: High out of specification results for levofloxacin resulting in increased concentration of solution.Baxter Healthcare Corporation · D-1215-2018Class IITerminatedOct 3, 2018Montelukast Sodium TabletsDiscoloration: A complaint was received from a pharmacist for the presence of blue specks on tablets.Hetero Labs Limited Unit V · D-1213-2018Class IIITerminatedOct 3, 2018Fenofibrate TabletsPresence of Foreign Tablet/Capsule: A foreign identified as Valacyclovir tablet 500 mg was co-mingled in a bottle containing Fenofibrate Tablets, USP 145 mg.Hetero Labs, Ltd. - Unit III · D-1211-2018Class IITerminatedOct 3, 2018MinivelleDefective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches.Noven Pharmaceuticals, Inc. · D-1210-2018Class IITerminatedOct 3, 2018MinivelleDefective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches.Noven Pharmaceuticals, Inc. · D-1209-2018Class IITerminatedOct 3, 2018MinivelleDefective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches.Noven Pharmaceuticals, Inc. · D-1208-2018Class IITerminatedOct 3, 2018MinivelleDefective Delivery System: out of specification results for shear, an attribute related to the adhesive properties of the transdermal patches.Noven Pharmaceuticals, Inc. · D-1207-2018Class IIITerminatedOct 3, 2018Zoledronic Acid InjectionFailed Impurities/Degradation Specifications: OOS for unknown impurities.Dr. Reddy's Laboratories, Inc. · D-0104-2019Class IIITerminatedOct 3, 2018Zoledronic Acid InjectionFailed Impurities/Degradation Specifications: OOS for unknown impurities.Dr. Reddy's Laboratories, Inc. · D-0103-2019Class IOngoingOct 3, 2018Montelukast Sodium Tablets 10 mgLabeling: Label Mix-Up - One lot labeled Montelukast Sodium Tablets 10 mg tablets may contain 90 tablets of Losartan Potassium 50 mg.Hetero Labs Limited Unit V · D-0081-2019Class IIITerminatedSep 26, 2018Morphine Sulfate Extended-Release TabletsFailed Impurities/Degradation Specifications: Morphine Sulfate Extended Release Tablets are being recalled due to out of Specification Result noticed for Morphinone...Lupin Somerset · D-1214-2018Class IIITerminatedSep 26, 2018Bupropion Hydrochloride ER TabletsFailed impurities/ degradation specifications: Out-of-specification results were observed in the meta-chlorobenzoic acid impurity in batches 18 months or older from date...InvaGen Pharmaceuticals, Inc. · D-1212-2018